Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cerecin

Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms
From Cerecin
Via GlobeNewswire
Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022
From Cerecin
Via GlobeNewswire
Results of Pilot Study of CER-0001 in Migraine support advancement into a pivotal global Phase 2/3 study
From Cerecin
Via GlobeNewswire
Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer
From Cerecin
Via GlobeNewswire
Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development
From Cerecin
Via GlobeNewswire
Tickers NSRGY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.